U.S. flu diagnostic and treatment market is projected to grow at a CAGR of 9.17% throughout the forecast period. According to the CDC (Center for Disease Control and Prevention), influenza is the leading cause of death by a vaccine-preventable disease and the eighth leading cause of death in the United States, together with pneumonia. Seasonal influenza results in more than US$10 billion of a total economic burden to the country’s healthcare system and society per year.The increasing number of flu cases in the country is significantly fuelling the market growth of the United States flu diagnostic and treatment market. There is a high intensity of seasonal flu outbreaks in the country. For the 2018-19 flu season (October 1, 2018-May 4, 2019), the CDC estimated up to 42.9 million cases of flu, up to 647,000 hospitalizations, and up to 61,200 flu deaths. This high intensity is attributed to the rising number of people suffering from chronic diseases and a growing geriatric population in the country. According to the United States Census Bureau, all baby boomers will be older than age 65 by 2030, expanding the size of the older population such that 1 in every 5 residents will be at retirement age. Also, 6 in 10 adults in the U.S. suffer from chronic disease. As a result, the rise in the number of hospitalizations due to influenza-like illness (ILI) is spurring the demand for flu diagnostic kits and treatment solutions in the country. Declining flu vaccination rates in the country is also a driving factor for the growing flu diagnostic and treatment market in the United States. According to a survey by the National Foundation for Infectious Diseases (NFID) 2018, although 60 percent of the American population think of flu vaccine as the best preventive measure against flu-related deaths and hospitalizations, only 52 percent planned to get one in 2019. The well-established healthcare sector in the country is also driving the market growth of flu diagnostic and treatment market.
The United States flu diagnostic and treatment market has been segmented on the basis of the type of flu, offering, age group, and end-user. On the basis of the type of flu, the market has been classified on the basis of type A and type B. By offering, the market has been segmented into diagnostics and therapeutics. By the age group, the U.S. flu diagnostic and treatment market has been segmented on the basis of 0-14 years, 15-64 years and >=65 years. By the end-user, the market segmentation has been done on the basis of hospital laboratory, outpatient clinic, and reference laboratory.
Prominent key market players in the U.S. flu diagnostic and treatment market include Abbott, F. Hoffmann-La Roche Ltd, Quidel Corporation, 3M, BD, and Thermo Fisher Scientific Inc. These companies hold a noteworthy share in the market on account of their good brand image and product offerings. Major players in the U.S. flu diagnostic and treatment market have been covered along with their relative competitive position and strategies. The report also mentions recent deals and investments of different market players over the last two years.